BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed AZN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:626b3c69c12832289c04@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261124
DTEND;VALUE=DATE:20261125
SUMMARY:AZN P1/P2 readout (est.): APOLLO
DESCRIPTION:Study of AZD0754 in Participants With Metastatic Prostate Cance
 r\nNCT06267729 | PHASE1/PHASE2 | RECRUITING | sponsor: AstraZeneca\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nTi
 cker AZN (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT062
 67729\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06267729
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c1c142320d2f5e02f2cb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AZN P2 readout (est.): TREMENDOUS-2
DESCRIPTION:Durvalumab and Tremelimumab With Lenvatinib as First-line Treat
 ment in Patients With Unresectable Hepatocellular Carcinoma\nNCT07081633 |
  PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07081633\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07081633
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:b4f76c4976a1c9a3c6ec@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:AZN P2 readout (est.): BaxDuo-Baltic
DESCRIPTION:A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Co
 mbination With Baxdrostat Compared With Baxdrostat on Albuminuria in Parti
 cipants With Chronic Kidney Disease and High Blood Pressure.\nNCT07222917 
 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (c
 onfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07222917\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07222917
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:52be3d9371de80389977@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:AZN P3 readout (est.): DOMINICA
DESCRIPTION:A Multicentre\, Randomised\, Double-blind\, Parallel Group\, Pl
 acebo-controlled\, Time-to-first Asthma Exacerbation Phase III Efficacy an
 d Safety Study of Benralizumab in Paediatric Patients With Severe Eosinoph
 ilic Asthma\nNCT05692180 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Astra
 Zeneca\nPrimary completion date (ESTIMATED)\; top-line results usually fol
 low later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltrials.go
 v/study/NCT05692180\nScheduling/reference data from public records\; dates
  can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05692180
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f65016d30b8660c65cc3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AZN P3 readout (est.): ROSY-D
DESCRIPTION:Roll Over StudY for Patients Who Have Completed a Previous Onco
 logy Study With Durvalumab\nNCT05303532 | PHASE3 | ENROLLING_BY_INVITATION
  | sponsor: AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line re
 sults usually follow later.\nTicker AZN (confidence 0.9)\nSource: https://
 clinicaltrials.gov/study/NCT05303532\nScheduling/reference data from publi
 c records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05303532
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:383c4d9be23a3c5382dc@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:AZN P3 readout (est.): AZURE-HeFH
DESCRIPTION:A Phase III Study to Assess the Effect of AZD0780 on LDL-C in P
 atients With HeFH\nNCT07000136 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT07000136\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07000136
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:663aa53ce97540b103ba@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270106
DTEND;VALUE=DATE:20270107
SUMMARY:AZN P3 readout (est.): DAISY
DESCRIPTION:Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (D
 AISY)\nNCT05925803 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca
 \nPrimary completion date (ESTIMATED)\; top-line results usually follow la
 ter.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltrials.gov/stud
 y/NCT05925803\nScheduling/reference data from public records\; dates can m
 ove. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05925803
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9edb17adc53239b9a0d8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:AZN P3 readout (est.): PACIFIC-9
DESCRIPTION:A Global Study to Assess the Effects of Durvalumab With Oleclum
 ab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in P
 atients With Stage III Unresectable Non-Small Cell Lung Cancer\nNCT0522184
 0 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT05221840\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05221840
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3c96d4e3ce020f1a20de@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:AZN P3 readout (est.): TROPION-Lung15
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Dato-DXd With
  or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy 
 in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small
  Cell Lung Cancer\nNCT06417814 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor:
  AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line results usual
 ly follow later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltri
 als.gov/study/NCT06417814\nScheduling/reference data from public records\;
  dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06417814
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e45a0b4143be80897193@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:AZN P3 readout (est.): AZURE-LDL
DESCRIPTION:A Phase III Study to Assess the Effect of AZD0780 on LDL-C in P
 atients With Clinical ASCVD or at Risk for a First ASCVD Event\nNCT0700012
 3 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN 
 (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07000123\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07000123
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:68007489a63a489ea8fa@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:AZN P3 readout (est.): ESSENCE
DESCRIPTION:A Study to Investigate Changes in Symptoms in Adult Participant
 s With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment Wi
 th Tezepelumab\nNCT06706817 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: As
 traZeneca\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker AZN (confidence 0.9)\nSource: https://clinicaltrials
 .gov/study/NCT06706817\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06706817
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:286ab689ac6188663d1f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:AZN P2 readout (est.): SOUND
DESCRIPTION:Savolitinib Combine With Durvalumab in EGFR Wild-type Locally A
 dvanced or Metastatic NSCLC\nNCT05374603 | PHASE2 | ACTIVE_NOT_RECRUITING 
 | sponsor: AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nTicker AZN (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT05374603\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05374603
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:dee46dcc9cb6fc3d86e8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:AZN P1/P2 readout (est.): CONTEMPO
DESCRIPTION:A Trial to Learn How Safe AZD9550 Monotherapy and Combined With
  AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With 
 Obesity and Overweight\nNCT06151964 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITIN
 G | sponsor: AstraZeneca\nPrimary completion date (ESTIMATED)\; top-line r
 esults usually follow later.\nTicker AZN (confidence 0.9)\nSource: https:/
 /clinicaltrials.gov/study/NCT06151964\nScheduling/reference data from publ
 ic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06151964
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:f92c1283693a4b7dcd5c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:AZN P2 readout (est.): A Study of T-DXd as Monotherapy or in Combin
 ation With Anti-cancer Agents in Patients With Selected HER2-expressing Tu
 mors
DESCRIPTION:A Study of T-DXd as Monotherapy or in Combination With Anti-can
 cer Agents in Patients With Selected HER2-expressing Tumors\nNCT06271837 |
  PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: AstraZeneca\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06271837\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06271837
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7248980a03b8eeee17c6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:AZN P2 readout (est.): SERENIA
DESCRIPTION:A Study to Investigate the Efficacy\, Safety\, and Tolerability
  of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.\nNC
 T07215702 | PHASE2 | RECRUITING | sponsor: AstraZeneca\nPrimary completion
  date (ESTIMATED)\; top-line results usually follow later.\nTicker AZN (co
 nfidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT07215702\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07215702
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7f556f922d7447ac9f94@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261113
DTEND;VALUE=DATE:20261114
SUMMARY:AZN APPROVAL: IMFINZI
DESCRIPTION:Approved 2026-11-13: IMFINZI (BLA761069 SUPPL59)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761069
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:42c135cd435208ff20a7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261008
DTEND;VALUE=DATE:20261009
SUMMARY:AZN APPROVAL: BREZTRI AEROSPHERE
DESCRIPTION:Approved 2026-10-08: BREZTRI AEROSPHERE (NDA220290 ORIG1)\nConf
 idence: confirmed\nTicker AZN (confidence 0.6)\nSource: https://www.access
 data.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=2202
 90\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220290
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:e16b0379fe964915d19a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260916
DTEND;VALUE=DATE:20260917
SUMMARY:AZN APPROVAL: TRUQAP
DESCRIPTION:Approved 2026-09-16: TRUQAP (NDA218197 SUPPL6)\nConfidence: con
 firmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218197
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:2b8764162a0ac6974784@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260914
DTEND;VALUE=DATE:20260915
SUMMARY:AZN APPROVAL: TAGRISSO
DESCRIPTION:Approved 2026-09-14: TAGRISSO (NDA208065 SUPPL35)\nConfidence: 
 confirmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=208065
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:03b7fa12f94865389b12@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260904
DTEND;VALUE=DATE:20260905
SUMMARY:AZN APPROVAL: ETCAMAH
DESCRIPTION:Approved 2026-09-04: ETCAMAH (NDA220359 ORIG1)\nConfidence: con
 firmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220359\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220359
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:9445dd3696800e30640a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260612
DTEND;VALUE=DATE:20260613
SUMMARY:AZN APPROVAL: TRUQAP
DESCRIPTION:Approved 2026-06-12: TRUQAP (NDA218197 SUPPL4)\nConfidence: con
 firmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=218197
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:81f18cfee64b7d4bf1bf@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260528
DTEND;VALUE=DATE:20260529
SUMMARY:AZN APPROVAL: IMFINZI
DESCRIPTION:Approved 2026-05-28: IMFINZI (BLA761069 SUPPL53)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761069
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7191b76ea2db0252de83@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260515
DTEND;VALUE=DATE:20260516
SUMMARY:AZN APPROVAL: BAXFENDY
DESCRIPTION:Approved 2026-05-15: BAXFENDY (NDA219878 ORIG1)\nConfidence: co
 nfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219878\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=219878
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:4c57d17425b42f8420a8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260513
DTEND;VALUE=DATE:20260514
SUMMARY:AZN APPROVAL: FASENRA
DESCRIPTION:Approved 2026-05-13: FASENRA (BLA761070 SUPPL23)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761070\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761070
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:827e43a85751cbeb40f3@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260430
DTEND;VALUE=DATE:20260501
SUMMARY:AZN ADCOM (scheduled): AdCom 2026-04-30: Oncologic Drugs Advisory C
 ommittee - NDA 220359\, sNDA 218197/S-004
DESCRIPTION:AdCom 2026-04-30: Oncologic Drugs Advisory Committee - NDA 2203
 59\, sNDA 218197/S-004\nConfidence: scheduled\nTicker AZN (confidence 0.6)
 \nSource: https://www.federalregister.gov/documents/2026/03/09/2026-04497/
 oncologic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-pu
 blic-docket-request-for\nScheduling/reference data from public records\; d
 ates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.federalregister.gov/documents/2026/03/09/2026-04497/oncolog
 ic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public-do
 cket-request-for
CATEGORIES:adcom,scheduled
END:VEVENT
BEGIN:VEVENT
UID:0de14595cd6fdb058c83@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260427
DTEND;VALUE=DATE:20260428
SUMMARY:AZN APPROVAL: SYMBICORT AEROSPHERE
DESCRIPTION:Approved 2026-04-27: SYMBICORT AEROSPHERE (NDA216579 SUPPL1)\nC
 onfidence: confirmed\nTicker AZN (confidence 0.9)\nSource: https://www.acc
 essdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=2
 16579\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=216579
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:32197edb0885ce61745b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260427
DTEND;VALUE=DATE:20260428
SUMMARY:AZN APPROVAL: BREZTRI AEROSPHERE
DESCRIPTION:Approved 2026-04-27: BREZTRI AEROSPHERE (NDA212122 SUPPL9)\nCon
 fidence: confirmed\nTicker AZN (confidence 0.6)\nSource: https://www.acces
 sdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212
 122\nScheduling/reference data from public records\; dates can move. Not i
 nvestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=212122
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:486a6cdc9680b2865136@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260424
DTEND;VALUE=DATE:20260425
SUMMARY:AZN APPROVAL: SAPHNELO
DESCRIPTION:Approved 2026-04-24: SAPHNELO (BLA761451 ORIG1)\nConfidence: co
 nfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761451\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761451
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:7ae3361e1282e7bccd75@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260415
DTEND;VALUE=DATE:20260416
SUMMARY:AZN APPROVAL: WAINUA\; WAINUA (AUTOINJECTOR)
DESCRIPTION:Approved 2026-04-15: WAINUA\; WAINUA (AUTOINJECTOR) (NDA217388 
 SUPPL5)\nConfidence: confirmed\nTicker AZN (confidence 0.6)\nSource: https
 ://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.proces
 s&ApplNo=217388\nScheduling/reference data from public records\; dates can
  move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=217388
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:18ce7fdef4ff89173017@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260219
DTEND;VALUE=DATE:20260220
SUMMARY:AZN APPROVAL: CALQUENCE
DESCRIPTION:Approved 2026-02-19: CALQUENCE (NDA210259 SUPPL12)\nConfidence:
  confirmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210259\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=210259
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:23ab4ea5536827a67fde@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260219
DTEND;VALUE=DATE:20260220
SUMMARY:AZN APPROVAL: CALQUENCE
DESCRIPTION:Approved 2026-02-19: CALQUENCE (NDA216387 SUPPL6)\nConfidence: 
 confirmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216387\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=216387
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:76391416d63306af3477@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251125
DTEND;VALUE=DATE:20251126
SUMMARY:AZN APPROVAL: IMFINZI
DESCRIPTION:Approved 2025-11-25: IMFINZI (BLA761069 SUPPL52)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.6)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761069
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:b503491afd96e6ee62f6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251119
DTEND;VALUE=DATE:20251120
SUMMARY:AZN APPROVAL: KOSELUGO
DESCRIPTION:Approved 2025-11-19: KOSELUGO (NDA213756 SUPPL6)\nConfidence: c
 onfirmed\nTicker AZN (confidence 0.9)\nSource: https://www.accessdata.fda.
 gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213756\nSched
 uling/reference data from public records\; dates can move. Not investment\
 , legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=213756
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
